This Week in Ophthalmology — Jun 26, 2026

Welcome to This Week in Ophthalmology. This week we're covering 9 notable papers spanning key advancements in retinal disease management, corneal and ocular surface health, and new predictive models for optic nerve pathology. Let's dive in.

Let's start with new insights into age-related macular degeneration and diabetic eye disease. In a target trial emulation using data from the TriNetX United States Collaborative Network, researchers evaluated whether dopamine-enhancing therapies could reduce the risk of converting from dry to neovascular age-related macular degeneration [6]. Analyzing adult patients with non-neovascular disease over a three-year period, they found that those prescribed levodopa with or without carbidopa had a significant reduction in conversion risk, showing roughly a thirty percent lower rate compared to matched controls. The study utilized a target trial emulation framework to minimize confounding, comparing new users of levodopa or dopamine receptor D2 agonists against patients prescribed pantoprazole or gabapentin as active controls. This rigorous methodology strengthens the finding that levodopa may play an active role in stabilizing the retinal pigment epithelium or choroidal vasculature, whereas direct receptor agonists like pramipexole or ropinirole do not share this protective association. This connects directly to a major study from the Ophthalmology journal using the Intelligent Research in Sight, or IRIS, Registry, which investigated whether cataract surgery accelerates conversion to neovascular age-related macular degeneration [9]. Looking at over eighty thousand eyes matched for baseline characteristics, the authors found a modest overall increase in conversion risk, with a hazard ratio of one point two two. However, a deeper time-varying analysis revealed that this risk was highly concentrated in the first year following surgery, where the hazard ratio was about two point five, and declined to non-significance by the fourth year. This pattern strongly suggests that the apparent risk is driven by intensive postoperative surveillance and the detection of pre-existing, unrecognized neovascular disease, rather than a true biological effect of cataract extraction. This is highly relevant for clinical practice, as it suggests we do not need to delay or avoid cataract surgery out of fear of accelerating macular degeneration, but we should remain vigilant in our pre-operative and early post-operative assessments.

Moving from age-related macular degeneration to diabetic macular edema, a nationwide registry-based cohort study published in the American Journal of Ophthalmology looked at the critical clinical scenario of patients returning after being lost to follow-up for six months or longer [8]. Among nearly one thousand patients who returned with active edema, about forty-six percent presented with stabilized visual acuity, while fifty-four percent had experienced a decline. When anti-vascular endothelial growth factor therapy was restarted, those who returned with stabilized vision actually had a much lower rate of visual improvement. Only about thirty-three percent gained vision, compared to sixty-two percent of those who had returned with vision loss. Crucially, patients who returned with stabilized vision of twenty-fifty or better achieved no visual gain at all despite anatomical improvement on optical coherence tomography. This suggests that for patients returning with moderate-to-good stable vision, immediate resumption of anti-vascular endothelial growth factor injections may offer limited functional benefits, and clinicians should carefully weigh retreatment against observation or alternative therapies. Early detection of diabetic retinal damage remains a priority, and a prospective cohort study in JAMA Ophthalmology investigated neuroretinal layer thinning in youth with type one diabetes [3]. Part of the ACCESS two study, researchers examined nearly three hundred pediatric patients using optical coherence tomography. They found that thinning of the ganglion cell plus inner plexiform layer and the outer retinal layers was significantly associated with higher hemoglobin A1c levels, even in youth who did not yet show any clinically visible diabetic retinopathy. The multivariable models demonstrated that for every one percent increase in hemoglobin A1c, there was a measurable decrease in the thickness of both the ganglion cell plus inner plexiform layer and the outer retinal layers. This is a vital piece of evidence showing that systemic glycemic control directly impacts neuroretinal structure long before microvascular lesions like microaneurysms or hemorrhages become visible on standard clinical exams.

Let's turn our attention to the cornea and ocular surface, where several new publications challenge current treatment paradigms and highlight systemic medication side effects. First, in infectious keratitis, the twelve-month results of the randomized, double-masked REAGIR trial were published in JAMA Ophthalmology [2]. The trial compared adjunctive rose bengal photodynamic therapy with green light irradiation to a sham procedure in three hundred thirty patients with fungal, acanthamoeba, or culture-negative corneal ulcers. Unfortunately, the long-term data confirm the six-month findings: there was no significant difference between the groups in best spectacle-corrected visual acuity, scar size, or rates of corneal perforation and therapeutic penetrating keratoplasty at one year. The lack of benefit was consistent across all subgroups, including fungal and acanthamoeba infections. This suggests that while rose bengal photodynamic therapy has demonstrated powerful in vitro antimicrobial properties, translating these effects to the complex in vivo corneal environment remains a significant hurdle, potentially due to limited tissue penetration or the rapid neutralizing capacity of corneal tissue. In oncology-related ocular side effects, a retrospective study in the American Journal of Ophthalmology systematically evaluated corneal changes associated with cyclin-dependent kinase four-six inhibitors, which are widely used for hormone receptor-positive breast cancer [4]. Because these drugs block the cell cycle, they can impair the highly proliferative corneal epithelium. The study compared women on combination therapy to those on aromatase inhibitors alone and healthy controls. They found that punctate epitheliopathy was remarkably common in the combination group, affecting over forty-four percent of eyes compared to less than five percent in the other groups. Furthermore, moderate-to-severe epitheliopathy and vortex keratopathy occurred exclusively in patients receiving the cyclin-dependent kinase four-six inhibitors. Because these patients often report low symptom scores, proactive corneal evaluation with fluorescein staining is highly recommended to catch these silent epithelial alterations early. On a broader scale of systemic medication effects, a systematic review and meta-analysis in the American Journal of Ophthalmology explored the controversial association between statin therapy and dry eye disease [7]. Pooling data from six observational studies involving over five hundred sixty thousand patients, the authors identified a small but statistically significant positive association, with statin users having about a nine percent increased odds of dry eye disease, translating to roughly ten additional cases per one thousand patients. Although the certainty of the evidence was graded as very low due to study design limitations, the consistent direction of the association across studies suggests that clinicians should actively monitor ocular surface symptoms in patients taking statins, especially those with pre-existing dry eye risk factors.

Our final theme explores predictive modeling for optic nerve damage and the structural biology of visual pigments. Managing highly myopic eyes presents a significant diagnostic challenge, particularly in distinguishing glaucomatous from non-glaucomatous optic neuropathy. The British Journal of Ophthalmology published the Two-Continent Eye Study, which developed and validated predictive equations for these conditions using data from over thirty-five thousand eyes across five large population-based cohorts [5]. The models incorporate axial length, age, intraocular pressure, ethnicity, and co-existing macular degeneration. The clinical utility of these equations is striking: for an individual with an axial length of twenty-eight millimeters and an intraocular pressure of twenty-two millimeters of mercury, the probability of glaucomatous optic neuropathy rises from three and a half percent at age thirty to over sixty percent by age seventy-five. If the axial length is thirty millimeters, that probability jumps to over seventy-five percent at age seventy-five, while the probability of non-glaucomatous optic neuropathy reaches over sixty-eight percent. These equations provide clinicians with a valuable tool to estimate long-term risk and tailor monitoring intervals for highly myopic patients. Finally, in a milestone paper for basic visual science, the journal Science published the first-ever cryo-electron microscopy structures of human cone visual pigments [1]. While the structure of rod-based rhodopsin has been known for over two decades, the structures of the long-, middle-, and short-wavelength-sensitive cone opsins had remained unsolved. The researchers successfully resolved all three human cone opsins bound to a G protein and all-trans-retinal in their active states. The structures reveal significant differences from rhodopsin, identifying a unique counterion site in the red and green opsins, and a distinct ring of serines surrounding the retinal in the blue opsin. These structural findings explain how specific amino acid substitutions fine-tune spectral sensitivity, providing a molecular explanation for color vision deficiencies and the fundamental differences in how our eyes transition between rod and cone vision.

If you only have time for one paper this week, make it the IRIS Registry study on cataract surgery and dry age-related macular degeneration conversion in the journal Ophthalmology [9]. This massive real-world analysis provides reassuring evidence that the apparent spike in neovascular conversion after cataract extraction is likely a temporary artifact of increased clinical surveillance rather than a biological consequence of surgery, allowing us to confidently counsel our patients with dry age-related macular degeneration.

Here are the key takeaways from this week in Ophthalmology. First, the twelve-month follow-up of the REAGIR trial confirms that adjunctive rose bengal photodynamic therapy does not improve visual or anatomical outcomes in moderate-to-severe infectious keratitis, suggesting we should stick to standard antimicrobial protocols. Second, when retreatments are initiated for diabetic macular edema patients returning after being lost to follow-up, those with stable baseline vision of twenty-fifty or better show poor visual recovery despite anatomical improvement, signaling a need for cautious, individualized retreatment decisions. Third, patients undergoing cyclin-dependent kinase four-six inhibitor therapy for breast cancer have a high rate of silent but severe punctate epitheliopathy and vortex keratopathy, making routine fluorescein staining essential during their oncologic treatment. Fourth, the Two-Continent Eye Study provides validated equations showing that the risk of both glaucomatous and non-glaucomatous optic neuropathies increases exponentially with age in highly myopic eyes, especially when axial length exceeds twenty-eight millimeters. And finally, systemic statin use is associated with a small but consistent increase in dry eye disease risk, so be sure to inquire about lipid-lowering therapies in patients presenting with unexplained ocular surface irritation.

That's your roundup for This Week in Ophthalmology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.